PCA-3 Reference Set Application: Zhang/Johns Hopkins: Glycoprotein Biomarkers for the Early Detection of Aggressive Prostate Cancer

Abbreviated Name
PCA3 Ref Set App: Zhang (2019)
Lead Investigator
Zhang, Hui L.Johns Hopkins University School of Medicine
Coordinating Investigator
Feng, Ziding Fred Hutchinson Cancer Center
Involved Investigators


see Objectives


We propose the following two aims: 1. Determine the performance of using urinary glycoproteomics and mass spectrometry for the detection of aggressive prostate cancer. We will (a) validate 4 candidate glycoproteins to detect AG PCa in diagnostic biopsy in the NCI-EDRNs Urinary PCA3 Evaluation Trial: (b) with PCA3 trial samples further develop a glycoproteomic risk score for predicting AG Pca in diagnostic biopsy; (c) validate the utility of glycoproteins separately and in combination to predict prostate cancer with a higher tumor grade (i.e., Gleason 3+4 or greater) at radical prostatectomy with NCI-EDRN Tissue Upgrading cohort. 2. Develop and apply ELISA assays to verify the candidate glycoproteins as non-invasive urinary tests for detecting aggressive prostate cancer.

Analytic Method


Data Collections

  • No data available at this time for this protocol
 Team Project
Protocol ID
Field of Research
Collaborative Group
Prostate and Urologic Cancers Research Group
Cancer Types
  • Malignant neoplasm of prostate
Phased Status

Associated Forms